Characterization of β-d- N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus

  • Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02395-16. doi: 10.1128/AAC.02395-16.
Maryam Ehteshami  1 ,  Sijia Tao  1 ,  Keivan Zandi  1  2 ,  Hui-Mien Hsiao  1 ,  Yong Jiang  1 ,  Emily Hammond  1 ,  Franck Amblard  1 ,  Olivia O Russell  1 ,  Andres Merits  3 ,  Raymond F Schinazi  4
Affiliations
  • 1. Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • 2. Tropical Infectious Disease Research and Education Center (TIDREC), Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • 3. Institute of Technology, University of Tartu, Tartu, Estonia.
  • 4. Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA [email protected].
PMID: 28137799 DOI: 10.1128/AAC.02395-16
Abstract

Chikungunya virus (CHIKV) represents a reemerging global threat to human health. Recent outbreaks across Asia, Europe, Africa, and the Caribbean have prompted renewed scientific interest in this mosquito-borne alphavirus. There are currently no vaccines against CHIKV, and treatment has been limited to nonspecific Antiviral agents, with suboptimal outcomes. Herein, we have identified β-d-N4-hydroxycytidine (NHC) as a novel inhibitor of CHIKV. NHC behaves as a pyrimidine ribonucleoside and selectively inhibits CHIKV replication in Cell Culture.

Keywords
Chikungunya virus; antiviral agents; nucleoside analogs; replicon.
Products